Zobrazeno 1 - 10
of 443
pro vyhledávání: '"RAS inhibitor"'
Autor:
Hirofumi Yoshino, Seiya Yokoyama, Motoki Tamai, Shunsuke Okamura, Sayaka Iizasa, Takashi Sakaguchi, Yoichi Osako, Satoru Inoguchi, Ryosuke Matsushita, Yasutoshi Yamada, Masayuki Nakagawa, Shuichi Tatarano, Akihide Tanimoto, Hideki Enokida
Publikováno v:
FEBS Open Bio, Vol 13, Iss 6, Pp 1056-1066 (2023)
Combination chemotherapy with gemcitabine and cisplatin (GC) is recommended as the primary treatment for advanced bladder cancer (BC). However, the benefits of this approach are limited owing to the acquisition of drug resistance. Here, we found that
Externí odkaz:
https://doaj.org/article/720e8450134c49778a8939c7650a0022
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Three rat sarcoma (RAS) gene isoforms, KRAS, NRAS, and HRAS, constitute the most mutated family of small GTPases in cancer. While the development of targeted immunotherapies has led to a substantial improvement in the overall survival of patients wit
Externí odkaz:
https://doaj.org/article/2890d2245f8249ce94c7c412c8ac5311
Publikováno v:
MedComm, Vol 4, Iss 3, Pp n/a-n/a (2023)
Abstract Rat sarcoma (RAS), as a frequently mutated oncogene, has been studied as an attractive target for treating RAS‐driven cancers for over four decades. However, it is until the recent success of kirsten‐RAS (KRAS)G12C inhibitor that RAS get
Externí odkaz:
https://doaj.org/article/8325c6ebe6ae43869590a32841c40e4a
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-23 (2022)
Abstract The RAS oncogene is both the most frequently mutated oncogene in human cancer and the first confirmed human oncogene to be discovered in 1982. After decades of research, in 2013, the Shokat lab achieved a seminal breakthrough by showing that
Externí odkaz:
https://doaj.org/article/a9615ec9bc634026bc11a210feb232f3
Autor:
Bolin Wu, Yanchi Yuan, Jiayin Liu, Haitao Shang, Jing Dong, Xitian Liang, Dongxu Wang, Yichi Chen, Chunyue Wang, Yang Zhou, Hui Jing, Wen Cheng
Publikováno v:
Journal of Nanobiotechnology, Vol 19, Iss 1, Pp 1-15 (2021)
Abstract Background Ras activation is a frequent event in hepatocellular carcinoma (HCC). Combining a RAS inhibitor with traditional clinical therapeutics might be hampered by a variety of side effects, thus hindering further clinical translation. He
Externí odkaz:
https://doaj.org/article/f5bf4e69bdc743a786e0c460782ae5e4
Autor:
Kyung-Hee Kim, Byoung Geol Choi, Seung-Woon Rha, Cheol Ung Choi, Myung-Ho Jeong, Other KAMIR-NIH investigators
Publikováno v:
BMC Cardiovascular Disorders, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background Patients with acute myocardial infarction (AMI) are usually treated with angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin receptor blockers (ARBs) if ACEIs are not tolerated. However, there is no data regarding the
Externí odkaz:
https://doaj.org/article/f9786c33bb4a47b0a7272107108451e7
Autor:
Sakuya Ito, Yosuke Nakayama, Goh Kodama, Kanji Ota, Kensei Taguchi, Yusuke Kaida, Sho-ichi Yamagishi, Kei Fukami
Publikováno v:
Renal Replacement Therapy, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Background Some types of antihypertensive drugs may have pleiotropic effects in patients with chronic kidney disease (CKD). However, whether triple combination therapy with angiotensin II receptor blockers (ARBs), calcium channel blockers (C
Externí odkaz:
https://doaj.org/article/3431b0f383f847698cb1d45549a1a913
Autor:
Antonio B. Ward, Adam B. Keeton, Xi Chen, Tyler E. Mattox, Alex B. Coley, Yulia Y. Maxuitenko, Donald J. Buchsbaum, Troy D. Randall, Gang Zhou, Gary A. Piazza
Publikováno v:
MedComm, Vol 1, Iss 2, Pp 121-128 (2020)
Abstract Approximately 30% of human cancers harbor a gain‐in‐function mutation in the RAS gene, resulting in constitutive activation of the RAS protein to stimulate downstream signaling, including the RAS‐mitogen activated protein kinase pathwa
Externí odkaz:
https://doaj.org/article/9aa12d1d00174415864d60bceb9ad752
Autor:
Fabian Hoffmann, Patricia Fassbender, Wilhelm Zander, Lisa Ulbrich, Kathrin Kuhr, Christoph Adler, Marcel Halbach, Hannes Reuter
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 9 (2022)
BackgroundMortality after ST-elevation myocardial infarction (STEMI) is dependent from best-medical treatment after initial event.ObjectivesDetermining the impact of prescription of guideline-recommended therapy after STEMI in two cohorts, patients w
Externí odkaz:
https://doaj.org/article/239ce5a00c03490da0bf6b948efa9476
Publikováno v:
Disease Models & Mechanisms, Vol 15, Iss 2 (2022)
Several cancers and rare genetic diseases are caused by dysregulation in the RAS signaling pathway. RAS proteins serve as molecular switches that regulate pathways involved in cellular growth, differentiation and survival. These pathways have been an
Externí odkaz:
https://doaj.org/article/e5c5cbfd2dc74fa28ae659cffcd069fe